

Exhibit 2

Agendas

Exhibit 2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
				#N/A		1740.00	#N/A	1a	F1-F2	09/10/2021	CGTH	2
						3320.00		1a	F1-F2	7/1/2021	ESP	2
				>11.0		8900000.00		1a	APRI 0.7	12/03/2022	ESP	2
				>11.0		699	#N/A	1a	F2 - Bridging fibrosis with few septa	09/29/2024	ESP	2
				>11.0		6910	#N/A	1b	F2 - Bridging fibrosis with few septa	08/01/2028	ESP	2
				>11.0		#N/A	#N/A	1a	F1-F2	09/14/2028	ESP	2
				>11.0		769	#N/A	1a	F1-F2	LWOP	ESP	2
				>11.0		3900.00	#N/A	4	F2 - Bridging fibrosis with few septa	LWOP	ESP	2
				>11.0	>11.0	2490.00	#N/A	1a	F1-F2	07/22/2021	FMWCC	2
				>11.0		3110.00	#N/A	1a	F2 - Bridging fibrosis with few septa	04/07/2022	FMWCC	2
				#N/A		1270.00	#N/A	2b	F2 - Bridging fibrosis with few septa	02/22/2027	FMWCC	2
				#N/A	>11.0	4920.00	#N/A	1b	F1-F2	LWOP	FMWCC	2
				>11.0		2360.00	#N/A	1a	F1-F2	04/06/2021	HDSP	2
				>11.0		#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	05/20/2021	HDSP	2
				>11.0		0.92	#N/A	Unable to determine the genotype on repeated attempts.	F1-F2	05/22/2021	HDSP	2
				>11.0		333.00	#N/A	3	F1-F2	09/06/2021	HDSP	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
				>11.0		10500000	#N/A	#N/A	F1-F2	09/12/2021	HDSP	2
				>11.0		#N/A	#N/A	#N/A	F1-F2	11/01/2021	HDSP	2
				>11.0		#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	12/22/2021	HDSP	2
				>11.0		#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	02/23/2022	HDSP	2
				>11.0		720.00	#N/A	1b	F2 - Bridging fibrosis with few septa	03/18/2022	HDSP	2
				#N/A	#N/A	3760.00	#N/A	3	F1 - Portal fibrosis	05/07/2021	LCC	3
				#N/A	#N/A	1220.00	#N/A	4	F2 - Bridging fibrosis with few septa	05/19/2021	LCC	2
				>11.0	Positive	4930.00	#N/A	2b	F0-F1	03/08/2022	LCC	3
				>11.0	Positive	290.00	#N/A	1a	F1-F2	08/22/2022	LCC	2
				>11.0	Positive	#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	01/17/2023	LCC	2
				#N/A	#N/A	11.80	#N/A	2b	F2 - Bridging fibrosis with few septa	03/19/2023	LCC	2
				>11.0	Positive	7.43	#N/A	1a	F0-F1	06/16/2023	LCC	3
				>11.0	Positive	2950.00	#N/A	1a	F1-F2	10/03/2023	LCC	2
				#N/A	#N/A	38.70	#N/A	1a	F2 - Bridging fibrosis with few septa	10/04/2023	LCC	2
				>11.0	Positive	PINC	14000	#N/A	F1-F2	11/27/2023	LCC	2
				>11.0	Positive	PINC	11500	1a	F1 - Portal fibrosis	01/29/2024	LCC	3
				>11.0	Positive	7770.00	#N/A	1a	F1-F2	03/31/2024	LCC	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
████	████	████	████	>11.0	Positive	6750.00	#N/A	1a	F1-F2	07/24/2024	LCC	2
████	████	████	████	>11.0	Positive	PINC	24500	1a	F2 - Bridging fibrosis with few septa	12/31/2024	LCC	2
████	████	████	████	>11.0	Positive	8810.00	#N/A	1a	F0-F1	01/10/2025	LCC	3
████████	████████	████████	████	>11.0	Positive	2600.00	#N/A	1a	F0-F1	01/18/2025	LCC	3
████████	████	████	████	>11.0	Positive	4690.00	#N/A	1a	F0 - No fibrosis	03/27/2025	LCC	3
████████	████	████	████	>11.0	Positive	#N/A	#N/A	#N/A	F1-F2	01/08/2026	LCC	2
████	████	████	████	>11.0	Positive	5330.00	#N/A	1b	F1-F2	03/17/2026	LCC	2
████	████	████	████	>11.0	Positive	142.00	#N/A	1b	F2 - Bridging fibrosis with few septa	10/14/2026	LCC	2
████	████	████	████	>11.0	Positive	241.00	#N/A	1a	F1-F2	01/31/2027	LCC	2
████	████	████	████	#N/A	#N/A	2420.00	#N/A	2b	F1-F2	03/29/2027	LCC	2
████████	████	████	████	>11.0	Positive	8700.00	#N/A	#N/A	F1-F2	01/14/2028	LCC	2
████████	████	████	████	>11.0	Positive	5810.00	#N/A	1b	F1-F2	06/09/2028	LCC	2
████████	████████	████	████	>11.0	Positive	5.77	#N/A	1a	F1-F2	10/22/2028	LCC	2
████	████████	████	████	>11.0	Positive	2320.00	#N/A	1b	F1-F2	08/01/2030	LCC	2
████████	████	████	████	>11.0	Positive	9390.00	#N/A	1a	F1 - Portal fibrosis	10/02/2030	LCC	3
████	████	████	████	>11.0	Positive	1220.00	#N/A	1a	F1-F2	09/05/2031	LCC	2
████████	████	████	████	>11.0	Positive	31.10	#N/A	3	F1-F2	10/21/2032	LCC	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
				>11.0	Positive	7270.00	#N/A	1a	F0-F1	06/12/2043	LCC	3
				>11.0	Positive	PINC	22600	1a	F1-F2	06/28/2081	LCC	2
				>11.0	Positive	1550.00	#N/A	1a	F1 - Portal fibrosis	Life - NPED 01/01/2022	LCC	3
				>11.0	Positive	PINC	26300	1a	F0-F1	Life - NPED 10/01/2023	LCC	3
				#N/A	#N/A	35.20	#N/A	1a	F1-F2	Life - PED 07/15/2024	LCC	2
				#N/A	#N/A	646.00	#N/A	1a	F1-F2	Life - PED 10/06/24 Safekeeper	LCC	2
				>11.0	Positive	4300.00	#N/A	1a	F1-F2	LWOP	LCC	2
				>11.0	Positive	8270.00	#N/A	1a	F1-F2	LWOP	LCC	2
				>11.0	Positive	HCVTND	#N/A	#N/A	F1 - Portal fibrosis	LWOP	LCC	3
				>11.0	Positive	#N/A	#N/A	1a	F2 - Bridging fibrosis with few septa	LWOP	LCC	2
				#N/A	#N/A	8180.00	#N/A	3	F1-F2	LWOP	LCC	2
				>11.0	Positive	51.00	#N/A	2b	F1-F2	LWOP	LCC	2
				>11.0	Positive	482.00	#N/A	1a	F0-F1	LWOP	LCC	3
				#N/A	#N/A	PINC	20700	2b	F1-F2	LWOP	LCC	2
				>11.0		#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	03/05/2021	NNCC	2
				#N/A		220	#N/A	2b	F2 - Bridging fibrosis with few septa	05/06/2021	NNCC	2
				>11.0		3570	#N/A	1a	F2 - Bridging fibrosis with few septa	06/03/2021	NNCC	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
				>11.0		90.80	#N/A	1a	F1-F2	06/13/2021	NNCC	2
				#N/A		2100.00	#N/A	1a	F2 - Bridging fibrosis with few septa	06/18/2021	NNCC	2
				>11.0		4730.00	#N/A	2b	F1-F2	08/13/2021	NNCC	2
				>11.0		2120.00	#N/A	1a	F2 - Bridging fibrosis with few septa	02/06/2022	NNCC	2
				>11.0		271.00	#N/A	1a	F2 - Bridging fibrosis with few septa	02/10/2022	NNCC	2
				>11.0		1400.00	#N/A	3	F1-F2	11/23/2021	NNTH	2
				>11.0		26.10	#N/A	1a	F1-F2	04/03/2021	PCC	2
				>11.0		4730.00	#N/A	1a	F1-F2	04/11/2022	PCC	2
				>11.0		133.00	#N/A	1a	F1-F2	08/02/2021	SCC	2
				>11.0		1140.00	#N/A	1a	F2 - Bridging fibrosis with few septa	10/30/2021	SCC	2
				#N/A		4020.00	#N/A	1a	F1-F2	09/21/2022	SCC	2
				>11.0		195000.00			F1-F2	09/27/2022	SCC	2
				>11.0		PINC	57500	1a	F2 - Bridging fibrosis with few septa	03/03/2024	SCC	2
				#N/A		130.00	#N/A	1a	F2 - Bridging fibrosis with few septa	06/09/2024	SCC	2
				>11.0		13.20	#N/A	3	F2 - Bridging fibrosis with few septa	06/27/2024	SCC	2
				#N/A		PINC	11800	1a	F1-F2	10/26/2026	SCC	2
				#N/A		PINC	28100	1a	F1-F2	04/26/2034	SCC	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
				>11.0		#N/A	#N/A	1a	F1-F2	04/16/2021	SDCC	2
				>11.0		0.65	#N/A	2b	F2 - Bridging fibrosis with few septa	07/23/2021	SDCC	2
				#N/A	>11.0	923.00	#N/A	1a	F1-F2	08/08/2021	SDCC	2
				>11.0		159.00	#N/A	More than one HCV genotype detected:	F1-F2	09/04/2021	SDCC	2
				>11.0		42.50	#N/A	3	F2 - Bridging fibrosis with few septa	04/27/2022	SDCC	2
				#N/A		1780.00	#N/A	1a	F1-F2	05/12/2022	SDCC	2
				>0.11		9240.00	#N/A	3	F1-F2	07/14/2022	SDCC	2
				#N/A		9980.00	#N/A	1a	F1-F2	05/02/2023	SDCC	2
				#N/A		70.60	#N/A	1a	F2 - Bridging fibrosis with few septa	09/22/2023	SDCC	2
				>11.0		#N/A	#N/A	#N/A	F2 - Bridging fibrosis with few septa	04/30/2021	TLVCC	2
				>11.0		192.00	#N/A	2b	F1-F2	07/14/2021	TLVCC	2
				#N/A		9520.00	#N/A	1a	F1-F2	09/16/2022	TLVCC	2
				#N/A		2630.00	#N/A	1a	F1-F2	09/09/2025	TLVCC	2
				>11.0		PINC	19300	1a	F1-F2	04/16/2021	WSCC	2
				>11.0		7290.00	#N/A	1a	F2 - Bridging fibrosis with few septa	05/17/2021	WSCC	2
				>11.0		PINC	18100	1a	F1-F2	06/10/2021	WSCC	2
				#N/A		PINC	18800	3	F2 - Bridging fibrosis with few septa	09/15/2021	WSCC	2

****CONSENT AGENDA******HCV Committee****January 13, 2021 Meeting**

NOTIS ID	NOTIS Last	NOTIS First	DOB	HCV Ab	HCV RNA NAA Qualitative	Hep C Quantitation	HCV RNA (IU)	Hep C Genotype	Fibrosis Stage	PEXD	Facility	Priority
████	████	████	████	>11.0		8500.00	#N/A	1a	F1-F2	08/02/2023	WSCC	2
██████████	████	████	████	#N/A		510.00	#N/A	3	F2 - Bridging fibrosis with few septa	09/09/2024	WSCC	2
██████████████	████	████	████	>11.0		113.00	#N/A	1a	F1-F2	01/28/2025	WSCC	2
██████████	████	████	████	>11.0		1240.00	#N/A	1a	F2 - Bridging fibrosis with few septa	02/26/2026	WSCC	2
██████████	████	████	████	#N/A	>11.0	18100	#N/A	1a	F1-F2	12/20/2026	WSCC	2
████	████	██████████	████	>11.0		25.70		1a	F2 - Bridging fibrosis with few septa	01/29/2028	WSCC	2